1% of oral dose for 30-fold lung exposure and reduced cardiotoxicityA cost-effective, easily accessible, user-friendly potential treatment/prevention option TLC19 utilizes TLC’s existing proprietary ...

This article is part of the Technology Insight series, made possible with funding from Intel. In case you hadn’t noticed, solid-state drives keep getting bigger and faster. Back in 2008, a ...

TAIPEI, Taiwan, April 03, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (“TLC”), a clinical-stage specialty pharmaceutical company dedicated to the development and ...